SV Health Investors Acquires EpiVax

The Boston-based biotech company EpiVax has been acquired by SV Health Investors.

Apr. 2, 2026 at 10:30pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a sleek, polished glass beaker filled with a vibrant blue liquid, representing the advanced biotechnology and scientific innovation of the EpiVax acquisition.The acquisition of EpiVax by SV Health Investors signals continued investment and growth in Boston's thriving biotech ecosystem.Boston Today

SV Health Investors, a leading healthcare-focused venture capital firm, has announced the acquisition of EpiVax, a Boston-based biotechnology company specializing in the development of immunotherapies and vaccines. The financial terms of the deal were not disclosed.

Why it matters

The acquisition of EpiVax by SV Health Investors signals continued investment and growth in the Boston biotech ecosystem, which has become a hub for innovative life sciences companies. This deal is expected to provide EpiVax with additional resources and expertise to accelerate the development of its pipeline of immunotherapies and vaccines.

The details

EpiVax was founded in 1998 and has developed a proprietary platform for the design and development of novel immunotherapies and vaccines. The company's technology leverages computational biology and bioinformatics to identify and target specific epitopes, which are the parts of an antigen that are recognized by the immune system.

  • SV Health Investors announced the acquisition of EpiVax on April 2, 2026.

The players

SV Health Investors

A leading healthcare-focused venture capital firm that invests in innovative life sciences companies.

EpiVax

A Boston-based biotechnology company that specializes in the development of immunotherapies and vaccines using a proprietary computational biology and bioinformatics platform.

Got photos? Submit your photos here. ›

The takeaway

The acquisition of EpiVax by SV Health Investors underscores the continued growth and investment in the Boston biotech ecosystem, which has become a hub for innovative life sciences companies. This deal is expected to provide EpiVax with additional resources and expertise to accelerate the development of its pipeline of immunotherapies and vaccines.